Publicaciones en colaboración con investigadores/as de Hospital Clinico Universitario de Valencia (43)

2024

  1. Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy

    npj Breast Cancer, Vol. 10, Núm. 1

  2. Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

    eClinicalMedicine, Vol. 71

2023

  1. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 7, pp. 1370-1375

  2. Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients

    Clinical Cancer Research, Vol. 29, Núm. 20, pp. 4166-4177

  3. CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 8, pp. 1557-1568

  4. HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer

    Frontiers in Oncology, Vol. 13

  5. Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study

    Annals of Oncology, Vol. 34, Núm. 8, pp. 670-680

  6. Spatial predictors of immunotherapy response in triple-negative breast cancer

    Nature, Vol. 621, Núm. 7980, pp. 868-876

2022

  1. Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer

    Clinical Cancer Research, Vol. 28, Núm. 5, pp. 93-1003

  2. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

    European Journal of Cancer, Vol. 168, pp. 12-24

  3. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

    Annals of Oncology, Vol. 33, Núm. 5, pp. 534-543

  4. Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial

    European Journal of Cancer, Vol. 174, pp. 232-242

  5. Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

    Breast, Vol. 66, pp. 77-84

2021

  1. First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study

    Frontiers in Oncology, Vol. 11

  2. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

    European Journal of Cancer, Vol. 156, pp. 70-82

  3. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

    Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499

  4. SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer

    Frontiers in Oncology, Vol. 11

2020

  1. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

    The Lancet Oncology, Vol. 21, Núm. 11, pp. 1455-1464

  2. A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study

    Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 420-428

  3. Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial

    Clinical Cancer Research, Vol. 26, Núm. 22, pp. 5820-5829